Clinical trial
DESIPHER Speech Degradation as an Indicator of Physiological Degeneration in ALS
NCT02675075 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- DESIPHER Speech Degradation as an Indicator of Physiological Degeneration in ALS
- Lead sponsor
- VA Office of Research and Development
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2016
- Completion date
- December 31, 2017
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.